FDA Grants IVIG 7-Year Market Exclusivity to Treat Adults with Dermatomyositis
The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis.
Source: The Rheumatologist - Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Pharma Co. News dermatomyositis dermatomyositis (DM) FDA FDA approval intravenous human immunoglobulin IVIg Octagam 10% U.S. Food and Drug Administration (FDA) Source Type: research
More News: Dermatology | Dermatomyositis | Food and Drug Administration (FDA) | Grants | Marketing | Pharmaceuticals | Rheumatology